ClinConnect ClinConnect Logo
Search / Trial NCT05805137

Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System

Launched by CUTOSENSE OY · Mar 28, 2023

Trial Information

Current as of July 25, 2025

Recruiting

Keywords

Venous Ulcer Monitoring Bioimpedance Electrode Array Wound Dressing

ClinConnect Summary

This clinical trial is looking at a new way to monitor the healing of venous ulcers, which are sores that can develop on the legs due to poor blood flow. The study is testing a special dressing that has electrodes, along with a device that measures how well the wound is healing and a mobile app for tracking progress. This method aims to help healthcare providers better understand how these wounds heal over time.

To participate in the study, you must be at least 18 years old and have a chronic ulcer caused by venous insufficiency, which means your veins are not working properly to return blood to your heart. The wound should be small (no larger than 5 x 5 cm), located above the ankle, and expected to heal within two months. If you are interested in joining, you’ll need to be able to attend the study site 2-3 times a week and follow the instructions from the medical team. If you have a current infection in the wound or certain health issues that affect blood flow, you may not be eligible. Overall, this study hopes to provide valuable insights into treating venous ulcers more effectively.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age at least 18 years
  • The subject has a chronic lower extremity ulcer with a primary etiology of venous insufficiency. The previous venous procedure is not an obstacle to the study
  • Compression therapy can be implemented
  • The wound is not wider than 5 cm and the electrode dressing can be placed on the wound as intended. The wound should be located above the ankle, on the skin area where the electrode dressing can be placed properly.
  • The wound is not deep with steep edges or cavity-like
  • The wound is not highly excreting
  • The wound can be expected to heal within two months (area reduced ≥ 90% from baseline)
  • The subject gives consent to the study and commits to following the instructions of the medical staff
  • Exclusion Criteria:
  • Clinical wound infection at the time of the study
  • The subject has an intravenous (in Tampere: A venous operation) procedure within 2 months
  • Significant arterial circulatory disorder or adherence problem that prevents compression therapy (in Tampere: Contraindication for compression therapy, e.g. significant arterial circulatory disorder or severe heart failure)
  • Subject movement 2-3 times a week during the study to the study site is difficult to arrange (in Tampere: Subject not able to commit to study visits 2-3 times a week.)
  • Diagnosed epoxy resin allergy
  • Any other reasons of potential study subject non-compliance by the opinion of the investigator
  • Additional local exclusion criteria in Tampere site:
  • Special groups, such as pregnant women/patients trying to conceive during the study or patients with reduced autonomy
  • Subject with any implantable electrical device. Such as pacemaker or implanted defibrillator. Patient has other electrically conductive implanted material in legs. Such as a metallic prostheses.

About Cutosense Oy

Cutosense Oy is an innovative clinical trial sponsor dedicated to advancing healthcare through cutting-edge research and development of medical technologies. With a strong focus on personalized medicine, Cutosense specializes in the development of wearable devices and digital health solutions designed to monitor and improve patient outcomes. The organization is committed to conducting rigorous clinical trials that adhere to the highest ethical standards and regulatory requirements, ensuring the safety and efficacy of its products. By leveraging data-driven insights and collaborating with healthcare professionals, Cutosense aims to transform patient care and deliver meaningful advancements in the field of health technology.

Locations

Gdańsk, , Poland

Tampere, , Finland

Patients applied

0 patients applied

Trial Officials

Piotr Spychalski, MD, Ph.D.

Principal Investigator

Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials